For research use only. Not for therapeutic Use.
L0909 is an orally available inhibitors of Hepatitis C virus with a novel mechanism of action (EC50 = 0.022 μM, SI > 600). L0909 could block HCV replication by acting on the HCV entry stage. The high sensitivity to clinical resistant HCV mutants and synergistic effect with clinical drugs were observed for this compound. L0909 as a promising HCV entry inhibitor for single or combinational therapeutic potential.
| Catalog Number | I030226 |
| CAS Number | 2085271-43-6 |
| Synonyms | L0909; L-0909; L 0909 |
| Molecular Formula | C23H30ClN5 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-4-((2-(dimethylamino)ethyl)(methyl)amino)benzonitrile |
| InChI | InChI=1S/C23H30ClN5/c1-26(2)10-11-27(3)23-7-4-19(17-25)20(16-23)18-28-12-14-29(15-13-28)22-8-5-21(24)6-9-22/h4-9,16H,10-15,18H2,1-3H3 |
| InChIKey | ZMKYHHMOPNGIDE-UHFFFAOYSA-N |
| SMILES | N#CC1=CC=C(N(CCN(C)C)C)C=C1CN2CCN(C3=CC=C(Cl)C=C3)CC2 |
| Reference | 1:Xinbei Jiang, Jiali Tan, Yixuan Wang, Jinhua Chen, Jianrui Li, Zhi Jiang, Yanni Quan, Jie Jin, Yuhuan Li, Shan Cen, Yanping Li, Zonggen Peng, and Zhuorong Li. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. Journal of Medicinal Chemistry Article ASAP. DOI: 10.1021/acs.jmedchem.0c00232 |
